Saving changes...

Done

Error

Pain Management: Non-Opioid and Adjuvant Analgesics

Pain Management: Non-Opioid and Adjuvant Analgesics

Pain Management: Non-Opioid and Adjuvant Analgesics

Andrew Lowe, Pharm.D.
Andrew Lowe, Pharm.D.
on behalf of Comprehensive Pharmacy Services

$50.00 $ 50.00 $ 50.00

$50.00 $ 50.00 $ 50.00

$ 50.00 $ 50.00 $ 50.00
$ 50.00 $ 50.00 $ 50.00
Normal Price: $50.00 $50.00

Review:

Launch date: 11 Jun 2018
Expiry Date: 20 Sep 2020

Last updated: 25 Jun 2018

Reference: 189744

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

The CPS Pain Management Program includes a series of presentations focusing on providing the pharmacist with the knowledge base needed to participate in the pain relief effort.
"Non-Opioid and Adjuvant Analgesics" addresses the pharmacology and therapeutic effects of non-opioid medications that have been effective in the treatment of pain. Specifically, this module discusses acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), antiepileptics, antidepressants, and muscle relaxants. The aim of this module is to encourage providers to use these medications to enhance pain relief and to decrease the use of opioids.
  
“Pain Management: Non-Opioid and Adjuvant Analgesics” is a PHARMACIST continuing pharmacy education (CPE) activity. This course is the home-study recording of an application activity originally presented by live webinar on Wednesday, September 20, 2017, for health-system pharmacists.
________________________________________
Learning Objectives
Upon completion of this activity, the pharmacist will be able to:
1. Determine when the use of anti-inflammatory therapy is appropriate
2. Outline pharmacology and adverse effects of cyclooxygenase inhibitors
3. Examine opioid-sparing therapy for neuropathic pain
4. Analyze the appropriate use of adjuvant analgesics, anticonvulsants, antidepressants, muscle relaxants, and anesthetics
5. Apply evidence-based recommendations for assessment and management of neuropathic pain in clinical practice
________________________________________

Participants must view the entire presentation, successfully complete the learning assessment in Rx Learning Center with a minimum score of 80%, and complete the course evaluation prior to claiming credit and receiving 1 contact hour or 0.1 CEU of continuing pharmacy education (CPE) credit. To claim CPE credit, participants must have their NABP e-profile ID, birth month, and birth day. Continuing pharmacy education (CPE) credit will be reported directly to CPE Monitor.
SPECIAL NOTE: Learners have only 60 days from the date of completion to claim CPE credit.
________________________________________
Accreditation for Pharmacists
Comprehensive Pharmacy Services is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 1 contact hour (0.1 CEU) of continuing pharmacy education credit for pharmacists (0085-0000-17-032-H01-P).

The topic designator for this activity is 01 and qualifies for Disease State Management/Drug Therapy CPE. The initial release date was 09/20/2017 and the planned expiration date is 09/20/2020.
No organization other than CPS has provided financial support for any component of this continuing pharmacy education activity.
In accordance with the Accreditation Council for Pharmacy Education's Guidelines for Standards for Commercial Support, CPS requires that all individuals involved in the development and delivery of program activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on presentations.

All faculty, reviewers and planners for CPS education activities are qualified and selected by CPS and required to disclose any relevant financial relationships with commercial interests. CPS identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity.

The faculty, reviewers and planners for this program declared in writing to the ACPE Program Administrator that they had no conflicts of interest or relationships pertinent to this activity.

CPS staff has no relevant financial relationships to disclose.

Objectives

Learning Objective One
Determine when the use of anti-inflammatory therapy is appropriate
Learning Objective Two
Outline pharmacology and adverse effects of cyclooxygenase inhibitors
Learning Objective Three
Examine opioid-sparing therapy for neuropathic pain
Learning Objective Four
Analyze the appropriate use of adjuvant analgesics, anticonvulsants, antidepressants, muscle relaxants, and anesthetics
Learning Objective Five
Apply evidence-based recommendations for assessment and management of neuropathic pain in clinical practice
Andrew Lowe, Pharm.D.

Author Information Play Video Bio

Andrew Lowe, Pharm.D.
on behalf of Comprehensive Pharmacy Services

Andy presently works for Comprehensive Pharmacy Services (CPS) as Regional Vice President - Clinical

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.00 Hours

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error